Evidence Tier: Phase 1-2 — AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that retains fat-metabolizing properties without the growth-promoting effects of full GH.
Overview
AOD-9604 was developed by Metabolic Pharmaceuticals Ltd. at Monash University, Australia. It is a modified version of the hGH fragment 176-191 with a tyrosine substitution that improves stability. Clinical development through Phase 2 did not demonstrate sufficient efficacy for FDA approval.
Regulatory Note
AOD-9604 received GRAS (Generally Recognized As Safe) status from the FDA in 2014 as a food ingredient, but this does not constitute approval as a therapeutic agent.
References
- Heffernan M, et al. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice." Endocrinology. 2001;142(12):5182-5189.
Research Disclaimer
This article is compiled from peer-reviewed research and publicly available scientific literature. It is intended for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health-related decisions.